Efficacy of acoramidis in transthyretin amyloid cardiomyopathy with and without atrial fibrillation: results from ATTRibute-CM. (Top) In this post hoc analysis of ATTRibute-CM, 611 participants with ATTR-CM were included in the efficacy analysis, and 420 participants (69%) had evidence of AF at baseline. (Left) In the modified intention-to-treat population, acoramidis lowered the risk of ACM or first CVH through Month 30 vs. placebo, regardless of baseline AF status. (Right) Compared with placebo, acoramidis reduced the frequency of new or worsening AF events (safety population) and was associated with a numerically lower frequency of AF-related CVH (modified intention-to-treat population).
ACM, all-cause mortality; AF, atrial fibrillation and/or atrial flutter; ATTR-CM, transthyretin amyloid cardiomyopathy; CVH, cardiovascular-related hospitalization; HR, hazard ratio.